These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 12664216

  • 1. Anti-CD20 monoclonal antibody treatment of Epstein-Barr virus-induced intrahepatic lymphoproliferative disorder following liver transplantation.
    Yedibela S, Reck T, Niedobitek G, Gramatzki M, Repp R, Hohenberger W, Ott R.
    Transpl Int; 2003 Mar; 16(3):197-201. PubMed ID: 12664216
    [Abstract] [Full Text] [Related]

  • 2. Anti-CD20 monoclonal antibody (Rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients.
    Serinet MO, Jacquemin E, Habes D, Debray D, Fabre M, Bernard O.
    J Pediatr Gastroenterol Nutr; 2002 Apr; 34(4):389-93. PubMed ID: 11930095
    [Abstract] [Full Text] [Related]

  • 3. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
    Chen DB, Wang Y, Song QJ, Shen DH.
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
    [Abstract] [Full Text] [Related]

  • 4. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication.
    Verschuuren EA, Stevens SJ, van Imhoff GW, Middeldorp JM, de Boer C, Koëter G, The TH, van Der Bij W.
    Transplantation; 2002 Jan 15; 73(1):100-4. PubMed ID: 11792987
    [Abstract] [Full Text] [Related]

  • 5. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder.
    Hart M, Thakral B, Yohe S, Balfour HH, Singh C, Spears M, McKenna RW.
    Am J Surg Pathol; 2014 Nov 15; 38(11):1522-9. PubMed ID: 25007145
    [Abstract] [Full Text] [Related]

  • 6. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
    Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, Neuhaus R, Lehmkuhl H, Horst HA, Salles G, Morschhauser F, Jaccard A, Lamy T, Leithäuser M, Zimmermann H, Anagnostopoulos I, Raphael M, Riess H, Choquet S, German PTLD Study Group, European PTLD Network.
    Lancet Oncol; 2012 Feb 15; 13(2):196-206. PubMed ID: 22173060
    [Abstract] [Full Text] [Related]

  • 7. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
    Styczynski J, Einsele H, Gil L, Ljungman P.
    Transpl Infect Dis; 2009 Oct 15; 11(5):383-92. PubMed ID: 19558376
    [Abstract] [Full Text] [Related]

  • 8. Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation.
    Blaes AH, Cao Q, Wagner JE, Young JA, Weisdorf DJ, Brunstein CG.
    Biol Blood Marrow Transplant; 2010 Feb 15; 16(2):287-91. PubMed ID: 19835968
    [Abstract] [Full Text] [Related]

  • 9. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy.
    Gulley ML, Swinnen LJ, Plaisance KT, Schnell C, Grogan TM, Schneider BG, Southwest Oncology Group.
    Transplantation; 2003 Sep 27; 76(6):959-64. PubMed ID: 14508361
    [Abstract] [Full Text] [Related]

  • 10. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation.
    Worth A, Conyers R, Cohen J, Jagani M, Chiesa R, Rao K, Goulden N, Veys P, Amrolia PJ.
    Br J Haematol; 2011 Nov 27; 155(3):377-85. PubMed ID: 21910716
    [Abstract] [Full Text] [Related]

  • 11. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder.
    Ganne V, Siddiqi N, Kamaplath B, Chang CC, Cohen EP, Bresnahan BA, Hariharan S.
    Clin Transplant; 2003 Oct 27; 17(5):417-22. PubMed ID: 14703923
    [Abstract] [Full Text] [Related]

  • 12. Epstein-Barr virus polymerase chain reaction-negative stage IV post-transplant lymphoproliferative disorder in a heart transplant patient treated with rituximab.
    Garceau P, Couture C, Cantin B, Bernier V, Sénéchal M.
    J Heart Lung Transplant; 2008 Aug 27; 27(8):928-31. PubMed ID: 18656811
    [Abstract] [Full Text] [Related]

  • 13. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation.
    Comoli P, Basso S, Zecca M, Pagliara D, Baldanti F, Bernardo ME, Barberi W, Moretta A, Labirio M, Paulli M, Furione M, Maccario R, Locatelli F.
    Am J Transplant; 2007 Jun 27; 7(6):1648-55. PubMed ID: 17511690
    [Abstract] [Full Text] [Related]

  • 14. Multiple clinical presentations of lymphoproliferative disorders in pediatric liver transplant recipients: a single-center experience.
    Pinho-Apezzato ML, Tannuri U, Tannuri AC, Mello ES, Lima F, Gibelli NE, Santos MM, Ayoub AA, Maksoud-Filho JG, Velhote MC, Silva MM, Andrade WC, Miyatani HT.
    Transplant Proc; 2010 Jun 27; 42(5):1763-8. PubMed ID: 20620519
    [Abstract] [Full Text] [Related]

  • 15. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease.
    Savoldo B, Rooney CM, Quiros-Tejeira RE, Caldwell Y, Wagner HJ, Lee T, Finegold MJ, Dotti G, Heslop HE, Goss JA.
    Am J Transplant; 2005 Mar 27; 5(3):566-72. PubMed ID: 15707412
    [Abstract] [Full Text] [Related]

  • 16. Posttransplantation lymphoproliferative disorders in pediatric patients undergoing liver transplantation.
    Koh BY, Rosenthal P, Medeiros LJ, Osorio RW, Roberts JP, Ascher NL, Gelb AB.
    Arch Pathol Lab Med; 2001 Mar 27; 125(3):337-43. PubMed ID: 11231479
    [Abstract] [Full Text] [Related]

  • 17. Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation.
    Zilz ND, Olson LJ, McGregor CG.
    J Heart Lung Transplant; 2001 Jul 27; 20(7):770-2. PubMed ID: 11448808
    [Abstract] [Full Text] [Related]

  • 18. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H, Hägglund H, Gustafsson-Jernberg A, LeBlanc K, Mattsson J, Remberger M, Ringdén O, Sparrelid E, Sundin M, Winiarski J, Yun Z, Ljungman P.
    Transpl Infect Dis; 2009 Oct 27; 11(5):393-9. PubMed ID: 19497070
    [Abstract] [Full Text] [Related]

  • 19. Posttransplant lymphoproliferative disorders in liver transplanted patients: a report of four cases.
    Lorenzini S, Andreone P, Gramenzi A, Morelli C, Zinzani PL, Grazi GL, Pileri S, Baccarani M, Tura S, Bernardi M.
    Transplant Proc; 2006 Jun 27; 38(5):1477-80. PubMed ID: 16797338
    [Abstract] [Full Text] [Related]

  • 20. Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.
    Miyagi S, Sekiguchi S, Kawagishi N, Akamatsu Y, Satoh K, Takeda I, Fukushima D, Kobayashi Y, Tokodai K, Fujimori K, Satomi S.
    Transplant Proc; 2011 Nov 27; 43(9):3299-301. PubMed ID: 22099782
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.